OOIR: Observatory of International Research

Papers

(The TQCC of Nature Reviews Nephrology is 17. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Cellular senescence: the good, the bad and the unknown	397
Clear cell renal cell carcinoma ontogeny and mechanisms of lethality	356
Pathophysiology of COVID-19-associated acute kidney injury	327
Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors	316
Mitochondrial quality control in kidney injury and repair	267
Hypertension-induced cognitive impairment: from pathophysiology to public health	264
Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease	213
The effect of HIF on metabolism and immunity	204
Epidemiology of haemodialysis outcomes	196
Randall’s plaque and calcium oxalate stone formation: role for immunity and inflammation	192
Cisplatin nephrotoxicity: new insights and therapeutic implications	185
Sepsis-associated acute kidney injury: consensus report of the 28th Acute Disease Quality Initiative workgroup	185
Kidney physiology and susceptibility to acute kidney injury: implications for renoprotection	170
Trajectories of kidney function in diabetes: a clinicopathological update	156
The fibrogenic niche in kidney fibrosis: components and mechanisms	156
Nitric oxide signalling in kidney regulation and cardiometabolic health	146
Pathogenesis of autoimmune disease	136
Postoperative acute kidney injury in adult non-cardiac surgery: joint consensus report of the Acute Disease Quality Initiative and PeriOperative Quality Initiative	123
Mineralocorticoid receptor antagonists in diabetic kidney disease — mechanistic and therapeutic effects	120
Pro-resolving lipid mediators: regulators of inflammation, metabolism and kidney function	119
Multi-omics integration in the age of million single-cell data	118
Sustainable Development Goals relevant to kidney health: an update on progress	114
Role of the cGAS–STING pathway in systemic and organ-specific diseases	111
Trained immunity — basic concepts and contributions to immunopathology	111
COVID-19 vaccination in kidney transplant recipients	110

Organ donation and transplantation: a multi-stakeholder call to action	110
Regulated cell death pathways in kidney disease	110
Therapeutic advances in COVID-19	103
Ferroptotic mechanisms and therapeutic targeting of iron metabolism and lipid peroxidation in the kidney	101
Patient-centred approaches for the management of unpleasant symptoms in kidney disease	99
Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence	98
The gut microbiome and hypertension	97
Association of metabolic dysfunction-associated fatty liver disease with kidney disease	96
Extracellular vesicles in kidney disease	94
Lipoproteins and fatty acids in chronic kidney disease: molecular and metabolic alterations	93
Liquid biopsies: donor-derived cell-free DNA for the detection of kidney allograft injury	92
COVID-19 vaccines and kidney disease	89
Glomerular hyperfiltration	88
The roles of tertiary lymphoid structures in chronic diseases	86
The genetics of kidney stone disease and nephrocalcinosis	86
Epidemiology of peritoneal dialysis outcomes	85
Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics	84
The COVID-19 pandemic: consequences for nephrology	83
Kidney and heart failure outcomes associated with SGLT2 inhibitor use	83
Renal microvascular endothelial cell responses in sepsis-induced acute kidney injury	82
Targeting innate immunity-driven inflammation in CKD and cardiovascular disease	80
Phenotypic diversity and metabolic specialization of renal endothelial cells	78
Advances in CRISPR therapeutics	78
Health inequities and the inappropriate use of race in nephrology	78
Pathophysiological mechanisms leading to muscle loss in chronic kidney disease	77
MicroRNAs in kidney injury and disease	77
Gasdermins and pyroptosis in the kidney	75
Circular RNAs in kidney disease and cancer	75
The role of immune cells and mediators in preeclampsia	75
Complosome — the intracellular complement system	74
Lipidomic approaches to dissect dysregulated lipid metabolism in kidney disease	72
COVID-19 vaccine hesitancy	72
Membranous nephropathy: new pathogenic mechanisms and their clinical implications	69
Long COVID and kidney disease	65
Chronic kidney disease and the global public health agenda: an international consensus	65
The impact of excessive salt intake on human health	64
Therapeutic trials in adult FSGS: lessons learned and the road forward	63
Clinical practice recommendations for primary hyperoxaluria: an expert consensus statement from ERKNet and OxalEurope	62
Tackling AKI: prevention, timing of dialysis and follow-up	60
Kidney lipid dysmetabolism and lipid droplet accumulation in chronic kidney disease	60
Key metalloproteinase-mediated pathways in the kidney	58
The Mesangial cell — the glomerular stromal cell	58
Vaccination in patients with kidney failure: lessons from COVID-19	58
Uraemic solutes as therapeutic targets in CKD-associated cardiovascular disease	57
Management of congenital nephrotic syndrome: consensus recommendations of the ERKNet-ESPN Working Group	57
The therapeutic potential of apelin in kidney disease	56
The evolving story of apolipoprotein L1 nephropathy: the end of the beginning	54
Progress in xenotransplantation: overcoming immune barriers	50
Conceptual advances and evolving terminology in acute kidney disease	49
Oxalate homeostasis	48

Experimental models of acute kidney injury for translational research	47
Aquaporin 2 regulation: implications for water balance and polycystic kidney diseases	47
Mapping the human kidney using single-cell genomics	46
Kidney and epigenetic mechanisms of salt-sensitive hypertension	45
Exercise and chronic kidney disease: potential mechanisms underlying the physiological benefits	44
COVID-19 and kidney disease: insights from epidemiology to inform clinical practice	43
The role of lysosomes in metabolic and autoimmune diseases	43
Oxidative stress and the role of redox signalling in chronic kidney disease	42
The nephropathy of sickle cell trait and sickle cell disease	41
Targeting immune cell metabolism in kidney diseases	41
Impact of the COVID-19 pandemic on the kidney community: lessons learned and future directions	38
Immunometabolic rewiring of tubular epithelial cells in kidney disease	38
Artificial intelligence-enabled decision support in nephrology	37
Mechanisms and consequences of sex differences in immune responses	36
Nutrient-sensing mTORC1 and AMPK pathways in chronic kidney diseases	36
The lymphatics in kidney health and disease	35
Activation and regulation of alloreactive T cell immunity in solid organ transplantation	35
Non-invasive molecular imaging of kidney diseases	35
Diagnosis and management of immune checkpoint inhibitor-associated acute kidney injury	34
The perils of misinformation: when health literacy goes awry	34
Ultrafiltration in critically ill patients treated with kidney replacement therapy	34
Unconventional T cells and kidney disease	34
Differences in the epidemiology, management and outcomes of kidney disease in men and women	34
Cardiac metabolic remodelling in chronic kidney disease	34
The evolving complexity of the collecting duct renin–angiotensin system in hypertension	33
Gut microbiome studies in CKD: opportunities, pitfalls and therapeutic potential	33
Nephron overload as a therapeutic target to maximize kidney lifespan	33
SGLT2 inhibitors may offer benefit beyond diabetes	32
Long COVID: long-term health outcomes and implications for policy and research	31
RNA-binding proteins and their role in kidney disease	28
Role of necroptosis in kidney health and disease	28
Inequities in kidney health and kidney care	27
Genetics of SLE: mechanistic insights from monogenic disease and disease-associated variants	26
The pathophysiology of distal renal tubular acidosis	26
Youth-onset type 2 diabetes mellitus: an urgent challenge	26
Principles of human and mouse nephron development	25
Pathogenic cellular and molecular mediators in lupus nephritis	25
Regulation of FGF23 production and phosphate metabolism by bone–kidney interactions	25
Biomimetic models of the glomerulus	25
Portable, wearable and implantable artificial kidney systems: needs, opportunities and challenges	24
Sex differences in energy metabolism: natural selection, mechanisms and consequences	23
Diagnosis of cardiovascular disease in patients with chronic kidney disease	23
Drosophila melanogaster: a simple genetic model of kidney structure, function and disease	23
Continuing kidney care in conflicts	23
The role of complement in kidney disease	23
Stony the road we trod: towards racial justice in kidney care	22
Regulation of nephron progenitor cell lifespan and nephron endowment	21
Kidney injury and disease in patients with haematological malignancies	20
The impact of intrauterine growth restriction and prematurity on nephron endowment	20
Patient-centred clinical trial design	20
Sex differences in renal transporters: assessment and functional consequences	20
Opioids for chronic pain management in patients with dialysis-dependent kidney failure	19
Managing climate change risks is imperative for human health	18
Immune cell behaviour and dynamics in the kidney — insights from in vivo imaging	18
Planar cell polarity pathway in kidney development, function and disease	18
Cell and gene therapy for kidney disease	18
Ferroptotic stress promotes the AKI to CKD transition	18
Role of perivascular cells in kidney homeostasis, inflammation, repair and fibrosis	17
The challenge of insomnia for patients on haemodialysis	17
The genetics and pathogenesis of CAKUT	17